ABOUT US
Mission statement
A life science company dedicated to the development of prognostic and predictive tests that will enhance personalized treatment strategies for cancer patients, to improve outcomes, and reduce costs.
PARP inhibitor therapy.
- PARP inhibitor therapy is currently approved for cancer therapy (ovarian, breast, prostate and pancreatic)
- PARPi (poly ADP ribose polymerase), include Olaparib, Rucaparib, Niraparib, Talazoparib.
- Prediction of PARP inhibitor therapy response requires improved marker development.
Predicting cancer therapeutic responses
Our preclinical studies have identified predictors of response to several cancer therapies including PARP inhibitors.